1,472,633 CVS Health Corporation $CVS Shares Sold by Pzena Investment Management LLC

Pzena Investment Management LLC trimmed its stake in shares of CVS Health Corporation (NYSE:CVS) by 12.5% in the third quarter, Holdings Channel reports. The fund owned 10,296,903 shares of the pharmacy operator’s stock after selling 1,472,633 shares during the period. CVS Health accounts for about 2.6% of Pzena Investment Management LLC’s portfolio, making the stock its 14th biggest position. Pzena Investment Management LLC’s holdings in CVS Health were worth $882,342,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Rakuten Investment Management Inc. increased its stake in CVS Health by 10.0% in the 3rd quarter. Rakuten Investment Management Inc. now owns 229,362 shares of the pharmacy operator’s stock valued at $19,977,000 after buying an additional 20,884 shares during the period. Provenance Wealth Advisors LLC raised its position in CVS Health by 296.3% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 4,550 shares of the pharmacy operator’s stock worth $390,000 after buying an additional 3,402 shares during the last quarter. Lyell Wealth Management LP lifted its stake in shares of CVS Health by 8.7% in the 3rd quarter. Lyell Wealth Management LP now owns 3,816 shares of the pharmacy operator’s stock worth $327,000 after acquiring an additional 304 shares during the period. Associated Banc Corp acquired a new stake in shares of CVS Health in the 3rd quarter worth $4,187,000. Finally, First Nebraska Trust Co purchased a new stake in shares of CVS Health in the third quarter valued at about $573,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE:CVS opened at $79.90 on Thursday. The company has a market cap of $102.19 billion, a P/E ratio of 21.14, a P/E/G ratio of 0.85 and a beta of 0.58. The firm’s 50 day moving average is $90.82 and its two-hundred day moving average is $88.86. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, topping the consensus estimate of $1.65 by $0.44. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $108.40 billion during the quarter, compared to analyst estimates of $104.72 billion. During the same period in the prior year, the firm posted $1.60 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Thursday, October 22nd were paid a dividend of $0.6650 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date was Thursday, October 22nd. CVS Health’s dividend payout ratio (DPR) is 70.37%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of recent analyst reports. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of CVS Health in a research report on Wednesday, September 9th. Piper Sandler set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. BMO Capital Markets set a $112.00 target price on CVS Health in a research note on Wednesday, September 9th. Wall Street Zen cut CVS Health from a “strong-buy” rating to a “buy” rating in a report on Monday, October 19th. Finally, Evercore restated an “outperform” rating on shares of CVS Health in a research note on Wednesday. Twenty-two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $109.46.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported Q3 adjusted earnings of $2.09 per share, above the $1.65 consensus estimate, while revenue rose 5.4% year over year to $108.4 billion. Management raised its 2026 adjusted EPS outlook to at least $8.20 from a prior range of $7.90–$8.10. CVS Q3 results and guidance
• Neutral Sentiment: The company plans to separate its retail pharmacy business from its health benefits, pharmacy-benefit and care operations, creating two publicly traded companies by the first half of 2028. CVS says the businesses could gain focus and strategic flexibility, though the separation is still more than a year away. CVS breakup plan
• Negative Sentiment: The breakup announcement appears to be the main overhang: investors are reacting warily to CVS reversing its vertically integrated strategy, including the Aetna combination, despite the earnings beat. The scale and complexity of unwinding the businesses may be fueling uncertainty around execution and the value of the new structure. Market reaction to CVS split plan

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.